Abstracts Archive - Page 839 of 2425 - ACR Meeting Abstracts

Abstract Number: 1209 • 2019 ACR/ARP Annual Meeting
Patient-reported Outcome Measures in Systemic Lupus Erythematosus: Use in Clinical Practice – Preliminary Results from the Integrate Project
Gamal Chehab¹, Jutta Richter ², Anna Kernder ¹, Chiara Tani ³, Valentina Lorenzoni ⁴, Elena Elefante ³, Ilaria Palla ⁵, Sara Cannizzo ⁶, Salvatore Pirri ⁶, Isotta Triulzi ⁵, Leopoldo Trieste ⁵, Giuseppe Turchetti ⁵, Marta Mosca ³ and Matthias Schneider ⁷, ¹Policlinic of Rheumatology and Hiller Research Unit Rheumatology, Heinrich-Heine-University, Duesseldorf, Germany, ²Department and Hiller Research Unit of Rheumatology, Heinrich-Heine University Duesseldorf, Duesseldorf, Nordrhein-Westfalen, Germany, ³Rheumatology Unit, Department of clinical and experimental medicine, University of Pisa, Pisa, Italy, ⁴Institute of Management , Scuola Superiore Sant'Anna, Pisa, Italy, ⁵Institute of Management, Scuola Superiore Sant'Anna, Pisa, Italy, ⁶Institute of Management, Scuola Superiore Sant'Anna, Pisa, Toscana, Italy, ⁷Policlinic for Rheumatology & Hiller Research Centre for Rheumatology, Heinrich-Heine-University Duesseldorf, Düsseldorf, Germany
Background/Purpose: Due to improved mortality and morbidity in systemic lupus erythematosus (SLE), non-clinical indicators and outcomes, especially patient-reported ones, have become increasingly important in disease…
Abstract Number: 1210 • 2019 ACR/ARP Annual Meeting
Utilization of a Multispecialty Team for the Diagnosis of Giant Cell Arteritis Reduces Patient Morbidity
Arash Hassantoufighi ¹, Rachel Lu-Do¹, Mamta Sherchan ¹, Christopher Collins ¹, Joshpaul Dhillon ² and Florina Constantinescu ¹, ¹MedStar Washington Hospital Center, Department of Rheumatology, Washington, DC, ²MedStar Washington Hospital Center, Department of Internal Medicine, Washington, DC
Background/Purpose: Giant Cell Arteritis (GCA) is an autoimmune vasculitis, most common in older adults with a peak incidence in the seventh decade. The diagnosis is…
Abstract Number: 1211 • 2019 ACR/ARP Annual Meeting
Improving Exercise Counselling of Patients with Inflammatory Arthritis: A Quality Improvement Project
Anwar Albasri ¹, Tariq Al-Araimi ¹, Stephanie Gottheil¹, Lauren King ¹, Sahil Koppikar ², Justin Shamis ¹, Shirley Lake ³ and Gakhal Natasha ¹, ¹University of Toronto, Toronto, Canada, ²University of Toronto, Markham, ON, Canada, ³Division of Rheumatology, Sunnybrook Hospital, Toronto, ON, Canada
Background/Purpose: Regular aerobic exercise has been shown to improve inflammatory arthritis (IA) symptoms and may reduce the risk of cardiovascular events observed in these patients.…
Abstract Number: 1212 • 2019 ACR/ARP Annual Meeting
Psychological Profile in Patients with Rheumatic Diseases in China: A Study of HADS Self-assessment with Smart System of Disease Management (SSDM)
Yongfu Wang¹, Jianhong Wu ², Yasong Li ³, Henglian Wu ⁴, Yang li ⁵, Hua Wei ⁶, Xiaoqi Chen ⁷, Bin Wu ⁸, Zhenbin li ⁹, Jinli Ru ¹⁰, Wenqiang Fan ¹¹, Shengguang Li ¹², Fang He ¹³, Yi Zhao ¹⁴, Fen Li ¹⁵, Bin Wu ¹⁶, Feng Wang ¹⁷, Miaojia Zhang ¹⁸, Lirong Kang ¹⁹, Hui Xiao ²⁰, Yuhua Jia ²¹, Bing Wu ²², Fei Xiao ²³ and Hui Song ²⁴, ¹The First Affiliated Hospital of BaoTou Medical College, Baotou, Nei Mongol, China (People's Republic), ²Dazhou Central Hospital, Dazhou, Sichuan, China (People's Republic), ³Zhejiang provincial people's hospital, Hangzhou, Zhejiang, China (People's Republic), ⁴Dongguan donghua hospital, Dongguan, Guangdong, China (People's Republic), ⁵The Second Affiliated Hospital of Harbin Medical University, Haerbin, China (People's Republic), ⁶Northern Jiangsu People's Hospital, Yangzhou, China (People's Republic), ⁷Zhongnan Hospital of Wuhan University, wuhan, China (People's Republic), ⁸The First People's Hospital of Jingzhou, jingzhou, China (People's Republic), ⁹The 980th Hospital of the PLA Joint Logistic Support Force, shijiazhuang, China (People's Republic), ¹⁰The Second Hospital of Shanxi Medical University, Shanxi, Shanxi, China (People's Republic), ¹¹Central Hospital of XinXiang, Xinxiang, Hainan, China (People's Republic), ¹²Peking University International Hospital, beijing, China (People's Republic), ¹³Suining Central Hospital, suining, China (People's Republic), ¹⁴Xuanwu Hospital, Capital Medical University, Beijing, China, beijing, China (People's Republic), ¹⁵The Second Xiangya Hospital of Central South University, changsha, China (People's Republic), ¹⁶Chongqing Hospital of Traditional Chinese Medicine, Chongqing, Chongqing, China (People's Republic), ¹⁷Central Hospital of Xiangyang, xiangyang, China (People's Republic), ¹⁸Jiangsu Province Hospital, The first affiliated hospital of Nanjing medical university, nanjing, China (People's Republic), ¹⁹The First Affiliated Hospital of BaoTou Medical College, baotou, China (People's Republic), ²⁰Shanghai Gothic Internet Technology Co., Ltd, shanghai, Shanghai, China (People's Republic), ²¹Shanghai Gothic Internet Technology Co., Ltd., Shanghai, Shanghai, China (People's Republic), ²²Shanghai Gothic Internet Technology Co., Ltd, Shanghai, China (People's Republic), ²³Shanghai Gothic Internet Technology Co., Ltd., shanghai, China (People's Republic), ²⁴Beijing Jishuitan Hospital, Beijing, Beijing, China (People's Republic)
Background/Purpose: The patients with chronic diseases such as rheumatic diseases suffer from physical pain and/or disability. In addition, psychological morbidities have also been found in…
Abstract Number: 1213 • 2019 ACR/ARP Annual Meeting
A Retrospective Review and Prospective Intervention for Outpatient Follow-Up of Hospitalized Patients in Rheumatology
Shakaib Hayat¹ and Stanley Ballou ², ¹Case Western Reserve University (MetroHealth), Cleveland, OH, ²Metrohealth medical center, Cleveland, OH
Background/Purpose: There is lack of appropriate outpatient follow-up (F/U) for hospitalized rheumatology patients, which can result in disease recurrence and recurrent inpatient admissions1. This is…
Abstract Number: 1214 • 2019 ACR/ARP Annual Meeting
The Effects of Pegloticase on Mean Arterial Blood Pressure: An Age Modulated Relationship?
Saadia Waheed¹, Hafiz Muhammad Zubair ², aamer ubaid ³, farishta waheed ³ and Linda Burns ⁴, ¹Sisters of Charity Hospital, Buffalo, NY, ²Sisters of Charity Hospital, buffalo, ³Khyber Teaching Hospital, Peshawar, Pakistan, ⁴Buffalo Rheumatology and Medicine, Buffalo
Background/Purpose: Multiple studies indicate hyperuricemia as an independent risk factor for hypertension. However, the association is found to be age-dependent and weakens as the patient…
Abstract Number: 1215 • 2019 ACR/ARP Annual Meeting
A Multicenter, Randomized, Double-blind, Placebo-controlled, Dose-Ranging Study to Evaluate Efficacy and Tolerability of SHR4640 in Patients with Hyperuricemia
Yanwei Lin¹, Xiaoxiang Chen ², Ping Ye ¹, Wenqin Geng ¹, Rui Ning ³, Yanfei Tai ³ and Chunde Bao ⁴, ¹Renji Hospital Affiliated to Shanghai Jiaotong University School of Medicine, Shanghai, China (People's Republic), ²Department of Rheumatology, Renji Hospital, Shanghai Jiaotong University School of medicine, Shanghai, China (People's Republic), ³Jiangsu Hengrui Medicine Co., Ltd, Shanghai, China (People's Republic), ⁴Department of Rheumatology, Renji Hospital, Shanghai Jiaotong University School of medicine, Shanghai, Shanghai, China (People's Republic)
Background/Purpose: Hyperuricemia, a common metabolic disorder, predisposes patients to develop gout due to the deposition of insoluble urate in joints. Safety concerns are frequently raised…
Abstract Number: 1216 • 2019 ACR/ARP Annual Meeting
Pilot, Randomized, Double-Blinded, Placebo Controlled Efficacy AndSafety Study of a Transdermal Alkalinizing and Pain Relieving Treatment ForAcute Gout Flare
Smitha Reddy¹, Ray Mabaquiao ² and Lisa Misell ³, ¹Arthritis Care and Research Inc., Poway, CA, ²Triwest Research, El Cajon, CA, ³Dyve Biosciences, San Diego, CA
Background/Purpose: Gout is characterized by a build-up of uric acid crystals in and around the joints. Uric acid crystal formation and dissolution is affected by…
Abstract Number: 1217 • 2019 ACR/ARP Annual Meeting
Phase 2 Dose-ranging Study of SEL-212 in Symptomatic Gout Patients: Selection of Doses for Further Clinical Development
Rehan Azeem¹, Alan Kivitz ², Horacio Plotkin ¹, Lloyd Johnston ¹, Takashi K. Kishimoto ¹, Justin Park ¹, Stephen Smolinski ¹ and Wesley DeHaan ¹, ¹Selecta Biosciences, Watertown, MA, ²Altoona Center for Clinical Research, Duncansville, PA
Background/Purpose: Gout is caused by the deposition of monosodium urate (MSU) crystals in joints due to chronic hyperuricemia. Long-term treatment focuses on reducing serum uric…
Abstract Number: 1218 • 2019 ACR/ARP Annual Meeting
Monthly Dosing of ImmTOR Tolerogenic Nanoparticles Combined with Pegylated Uricase (Pegadricase) Enables Sustained Reduction of Acute Gout Flares in Symptomatic Gout Patients
Rehan Azeem¹, Justin Park ¹, Horacio Plotkin ¹, Alan Kivitz ², Lloyd Johnston ¹, Takashi K. Kishimoto ¹, Stephen Smolinski ¹ and Wesley DeHaan ¹, ¹Selecta Biosciences, Watertown, MA, ²Altoona Center for Clinical Research, Duncansville, PA
Background/Purpose: Long term gout treatment focuses on reducing sUA levels, thus allowing MSU crystals to dissolve. Rapid dissolution of MSU crystals during initial phase of…
Abstract Number: 1219 • 2019 ACR/ARP Annual Meeting
Uric Acid Level as a Predictor of Long Term Mortality in Advanced Age Population
‪Gabriel Breuer‬‏¹, Marwan Abu Sneineh‬‏ ¹ and Gideon Nesher ¹, ¹Shaare Zedek Medical Center, Jerusalem, Yerushalayim, Israel
Background/Purpose: Hyperuricemia is associated with the development, progression and outcome of several diseases. The purpose of this study is to evaluate the serum uric acid…
Abstract Number: 1220 • 2019 ACR/ARP Annual Meeting
How Are Flares Reported in Long-term Gout Clinical Trials? A Content Analysis of Randomized Controlled Trials
Sarah Stewart¹, Amy Tallon ², William Taylor ³, Angelo Gaffo ⁴ and Nicola Dalbeth ², ¹University of Auckland, Auckland, Auckland, New Zealand, ²University of Auckland, Auckland, New Zealand, ³University of Otago, Otago, New Zealand, ⁴University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Prevention of gout flares is a central concern to patients with gout. There are many potential ways that gout flares could be reported in…
Abstract Number: 1221 • 2019 ACR/ARP Annual Meeting
Impact of Psoriasis Disease Activity and Other Risk Factors on Serum-urate Levels in Patients with Psoriasis and Psoriatic Arthritis – A Post-hoc Analysis of Pooled Data from Three Phase 3-trials with Secukinumab
Mats Dehlin¹, Andreas Fasth ², Maximilian Reinhardt ³ and Lennart Jacobsson ⁴, ¹Dept of Rheumatology and Inflammation Research, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Sweden, Gothenburg, Sweden, ²Medical Affairs, Novartis Sverige AB, Kista, Sweden, Stockholm, Sweden, ³Medical Affairs, Novartis Pharma GmbH, Nürnberg, Germany, Nürnberg, Germany, ⁴Dept of Rheumatology and Inflammation Research, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Sweden,, Gothenburg, Sweden
Background/Purpose: Increased serum uric acid (sUA), hyperuricemia, has been reported to be associated with psoriasis (1). Increased cell turnover in psoriatic skin lesions has been…
Abstract Number: 1222 • 2019 ACR/ARP Annual Meeting
Relationships Between Allopurinol Dose, Oxypurinol Levels and Serum Urate – in Search of an Oxypurinol Therapeutic Concentration
Lisa Stamp¹, Peter Chapman ², Murray Barclay ³, Anne Horne ⁴, Christopher Frampton ³, Tony Merriman ⁵, Daniel Wright ⁶, Jill Drake ³ and Nicola Dalbeth ⁴, ¹University of Otago, Christchurch, Christchurch, Canterbury, New Zealand, ²Christchurch Hospital, Christchurch, New Zealand, ³University of Otago, Christchurch, Christchurch, New Zealand, ⁴University of Auckland, Auckland, New Zealand, ⁵University of Otago, Birmingham, AL, ⁶University of Otago, Dunedin, New Zealand
Background/Purpose: Lack of a standardised allopurinol dose, with marked inter-individual variation in the dose required to achieve target urate contribute to failure to reach target…
Abstract Number: 1223 • 2019 ACR/ARP Annual Meeting
Enteral Administration of ALLN-346, a Recombinant Urate-degrading Enzyme, Decreases Serum Urate in a Pig Model of Hyperuricemia
Danica Grujic¹, Kateryna Pirzynowska ², Paulina Szczurek ³, Stefan Pierzynowski ², Aditi Desphande ⁴, Olha Drahanchuck ⁵, Nadia Mosiichuk ⁶ and Jarek Wolinski ⁷, ¹Allena Pharmaceuticals, Boston, ²Lund University, Anara AB,/SGPlus, Lund, Sweden, ³National Research Institute of Animal Production, Vitanano Sp. z o.o./PROF,, Balice, Poland, ⁴Allena Pharmaceuticals, Newton, MA, ⁵Polish Academy of Sciences, Vitanano Sp. z o.o./PROF,, Jablonna, Poland, ⁶Lund University, Lund, Sweden, ⁷Polish Academy of Sciences, Vitanano Sp. z o.o./PROF, Jablonna, Poland
Background/Purpose: Uric acid homeostasis is determined as a balance between production, intestinal secretion and renal excretion. Around 2/3 of uric acid is excreted by the…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].